Loading…
Moleculin Biotech, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in MBRX.
▼ -99.9% over 5Y.
today you would have $0.53▼ -99.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $3.31 | $42.50 | $321.75 | $397.50 | |
| P/B | 0.6x | 0.7x | 0.5x | 1.1x | 0.6x |
| EPS | -$28.42 | -$189.14 | -$376.75 | -$378.75 | |
| ROE | -168.91% | -223.64% | -232.41% | -114.18% | -55.61% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HCTIHealthcare Triangle, Inc. | $0.84 | — | 0.1x | — | -57.41% | $12.36M |
| IRIXIridex Corp | $0.71 | — | — | — | -73.15% | $12.3M |
| QNRXQuoin Pharmaceuticals Ltd. | $6.12 | — | 0.7x | — | -575.73% | $12.29M |
| PHIOPhio Pharmaceuticals Corp. | $1.13 |
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Company description provided by Yahoo Finance.
| — |
| 1.0x |
| — |
| -113.71% |
| $13.13M |
| KALAKALA BIO, Inc. | $0.69 | — | 1.5x | — | -345.32% | $13.35M |
| ASBPAspire Biopharma Holdings, Inc. | $8.51 | — | 0.9x | — | -1032.14% | $11.94M |